A leading association of eye doctors has warned its members about safety concerns about Novartis’ new eye drug, sending the company’s stock down sharply Monday while that of Regeneron Pharmaceuticals, which produces a competing product, rose.

The American Society of Retina Specialists sent its membership an email about the drug, Beovu, on Sunday, warning that some doctors were reporting not just a known side effect, eye inflammation, but also a new one, vasculitis. 

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • “Murray argued that it was important that health plans not dictate which drug patients try first for cost reasons.”- I wish he would have been asked why. Is it because he would not want to be dictated to use this drug with a safety signal, or because he he just thinks it is important that physicians can write any medication regardless of cost? Or, if he has evidence-based reasons to support why it is important.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy